Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00234494 · ClinicalTrials.gov registry record · Phase 2
Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer
A Phase 2 study, sponsored by Christopher Sweeney, MBBS.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00234494: Completed Phase 2 study, sponsored by Christopher Sweeney, MBBS.
NCT00234494 is a Phase 2 study that has completed, run by Christopher Sweeney, MBBS. The registered enrollment target is 45 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00234494, a Phase 2 study, has completed, sponsored by Christopher Sweeney, MBBS.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single agent gemcitabine has demonstrated an overall response rate (ORR) of approximately 25%, including some complete responses (CR), with minimal toxicity in patients with advanced bladder cancer. Bevacizumab, a murine anti-human VEGF monoclonal antibody, has been advanced for use in combination with cytotoxic chemotherapy to delay time to disease progression in patients with metastatic solid tumors. This trial is designed to further assess the efficacy, safety and tolerability of this regimen in this patient population.
Interventions
- DRUG Bevacizumab
- DRUG Cisplatin
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00234494
The ClinicalTrials.gov registry entry for NCT00234494 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Christopher Sweeney, MBBS, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00234494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00234494 about?
NCT00234494 is a clinical study titled "Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer". Cisplatin is a very important agent for the treatment of TCC as it has a single agent response rate of approximately 15%. However, it has been most important as a part of combination chemotherapy, MVAC initially and now in combination with gemcitabine. Single agent gemcitabine has demonstrated an ov...
What is the current status of trial NCT00234494?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2005-11. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00234494?
The interventions under investigation include: Bevacizumab (DRUG), Cisplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00234494?
This trial is sponsored by Christopher Sweeney, MBBS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.